Predictive Role of CEA and CYFRA 21-1 in Patients with
Advanced-stage NSCLC Treated with Erlotinib

J 2014

Predictive Role of CEA and CYFRA 21-1 in Patients with Advanced-stage NSCLC Treated with Erlotinib

FIALA, Ondrej; Milos PESEK; Jindrich FINEK; Lucie BENESOVA; Marek MINARIK et al.

Základní údaje

Originální název

Predictive Role of CEA and CYFRA 21-1 in Patients with Advanced-stage NSCLC Treated with Erlotinib

Autoři

FIALA, Ondrej; Milos PESEK; Jindrich FINEK; Lucie BENESOVA; Marek MINARIK; Zbyněk BORTLÍČEK a Ondrej TOPOLCAN

Vydání

Anticancer Research, Athens, The International Institute of Anticancer Research, 2014, 0250-7005

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.826

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/14:00076231

Organizační jednotka

Lékařská fakulta

UT WoS

000336875200067

Klíčová slova anglicky

Tumor marker; CEA; CYFRA 21-1; erlotinib; NSCLC; EGFR-TKI; prediction

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 27. 8. 2014 13:26, Soňa Böhmová

Anotace

V originále

Background: Tumor biomarkers are used for predicting therapy effect and prognosis of patients with non-small cell lung cancer (NSCLC). We focused on their potential role in prediction of the efficacy of erlotinib. Patients and Methods: In a total of 144 patients with advanced-stage (IIIB or IV) NSCLC treated with erlotinib, pre-treatment levels of soluble carcinoembryonic antigen (CEA) and cytokeratin markers in serum were measured. Results: The median progression-free and overall survival for patients with a high level of carcinoembryonic antigen (CEA) was 1.9 and 8.6 vs. 2.9 and 16.1 months for patients with low CEA (p=0.046 and p=0.116). The respective medians for patients with a high level of cytokeratin-19 fragment were 1.9 and 6.1 vs. 3.4 and 23.8 months for patients with the low cytokeratin-19 fragment (p<0.001 and p<0.001). Conclusion: High pre-treatment serum levels of one or both biomarkers are associated with poor outcome of patients with NSCLC treated with erlotinib.

Citovat

FIALA, Ondrej; Milos PESEK; Jindrich FINEK; Lucie BENESOVA; Marek MINARIK; Zbyněk BORTLÍČEK a Ondrej TOPOLCAN. Predictive Role of CEA and CYFRA 21-1 in Patients with Advanced-stage NSCLC Treated with Erlotinib. Anticancer Research. Athens: The International Institute of Anticancer Research, 2014, roč. 34, č. 6, s. 3205-3210. ISSN 0250-7005.

@article{1195738,
   author = {Fiala, Ondrej and Pesek, Milos and Finek, Jindrich and Benesova, Lucie and Minarik, Marek and Bortlíček, Zbyněk and Topolcan, Ondrej},
   article_location = {Athens},
   article_number = {6},
   keywords = {Tumor marker; CEA; CYFRA 21-1; erlotinib; NSCLC; EGFR-TKI; prediction},
   language = {eng},
   issn = {0250-7005},
   journal = {Anticancer Research},
   title = {Predictive Role of CEA and CYFRA 21-1 in Patients with Advanced-stage NSCLC Treated with Erlotinib},
   volume = {34},
   year = {2014}
}

TY  - JOUR
ID  - 1195738
AU  - Fiala, Ondrej - Pesek, Milos - Finek, Jindrich - Benesova, Lucie - Minarik, Marek - Bortlíček, Zbyněk - Topolcan, Ondrej
PY  - 2014
TI  - Predictive Role of CEA and CYFRA 21-1 in Patients with Advanced-stage NSCLC Treated with Erlotinib
JF  - Anticancer Research
VL  - 34
IS  - 6
SP  - 3205-3210
EP  - 3205-3210
PB  - The International Institute of Anticancer Research
SN  - 02507005
KW  - Tumor marker
KW  - CEA
KW  - CYFRA 21-1
KW  - erlotinib
KW  - NSCLC
KW  - EGFR-TKI
KW  - prediction
N2  - Background: Tumor biomarkers are used for predicting therapy effect and prognosis of patients with non-small cell lung cancer (NSCLC). We focused on their potential role in prediction of the efficacy of erlotinib. Patients and Methods: In a total of 144 patients with advanced-stage (IIIB or IV) NSCLC treated with erlotinib, pre-treatment levels of soluble carcinoembryonic antigen (CEA) and cytokeratin markers in serum were measured. Results: The median progression-free and overall survival for patients with a high level of carcinoembryonic antigen (CEA) was 1.9 and 8.6 vs. 2.9 and 16.1 months for patients with low CEA (p=0.046 and p=0.116). The respective medians for patients with a high level of cytokeratin-19 fragment were 1.9 and 6.1 vs. 3.4 and 23.8 months for patients with the low cytokeratin-19 fragment (p<0.001 and p<0.001). Conclusion: High pre-treatment serum levels of one or both biomarkers are associated with poor outcome of patients with NSCLC treated with erlotinib.
ER  -

FIALA, Ondrej; Milos PESEK; Jindrich FINEK; Lucie BENESOVA; Marek MINARIK; Zbyněk BORTLÍČEK a Ondrej TOPOLCAN. Predictive Role of CEA and CYFRA 21-1 in Patients with Advanced-stage NSCLC Treated with Erlotinib. \textit{Anticancer Research}. Athens: The International Institute of Anticancer Research, 2014, roč.~34, č.~6, s.~3205-3210. ISSN~0250-7005.

Přehled o publikaci